Display options
Cite
FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol. 2016;4(2):97-112doi: 10.14218/JCTH.2016.00007.
FakhriRavari, A., Malakouti, M., & Brady, R. (2016). Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. Journal of clinical and translational hepatology, 4(2), 97-112. https://doi.org/10.14218/JCTH.2016.00007
FakhriRavari, Alireza, et al. "Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection." Journal of clinical and translational hepatology vol. 4,2 (2016): 97-112. doi: https://doi.org/10.14218/JCTH.2016.00007
FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol. 2016 Jun 28;4(2):97-112. doi: 10.14218/JCTH.2016.00007. Epub 2016 Jun 15. PMID: 27350940; PMCID: PMC4913075.
Copy Download .nbib Format: NLM
Share it on

J Clin Transl Hepatol. 2016 Jun 28;4(2):97-112. doi: 10.14218/JCTH.2016.00007. Epub 2016 Jun 15.

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection.

Journal of clinical and translational hepatology

Alireza FakhriRavari, Mazyar Malakouti, Rebecca Brady

Affiliations

  1. Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USA.
  2. University of Texas Health Science Center, San Antonio, Texas, USA.

PMID: 27350940 PMCID: PMC4913075 DOI: 10.14218/JCTH.2016.00007

Abstract

Hepatitis C virus (HCV) infection affects as many as 185 million people globally, many of whom are chronically infected and progress over time to cirrhosis, decompensated liver disease, hepatocellular carcinoma, and eventually death without a liver transplant. In the United States, HCV genotype 1 constitutes about 75% of all infections. While interferon and ribavirin therapy was the cornerstone of treatment for many years, interferon-free treatments have become the standard of care with the emergence of new direct-acting agents, resulting in more effective treatment, shorter duration of therapy, better tolerability, lower pill burden, and ultimately better adherence. This review will summarize the evidence for the currently available combination therapies as well as emerging therapies in phase 3 trials for treatment of HCV genotype 1.

Keywords: Direct acting antiretroviral agents; Genotype 1; HCV; Hepatitis C

References

  1. N Engl J Med. 2014 Apr 17;370(16):1483-93 - PubMed
  2. J Med Chem. 2014 Mar 13;57(5):2047-57 - PubMed
  3. Gastroenterology. 2013 Jun;144(7):1450-1455.e2 - PubMed
  4. JAMA. 2012 Dec 26;308(24):2584-93 - PubMed
  5. Lancet. 2014 Nov 15;384(9956):1756-65 - PubMed
  6. N Engl J Med. 2014 Apr 24;370(17):1604-14 - PubMed
  7. Clin Pharmacokinet. 2015 Jul;54(7):677-90 - PubMed
  8. Expert Opin Drug Saf. 2015 Oct;14(10):1631-46 - PubMed
  9. N Engl J Med. 2014 May 22;370(21):1983-92 - PubMed
  10. JAMA. 2014 Aug 13;312(6):631-40 - PubMed
  11. N Engl J Med. 1998 Nov 19;339(21):1485-92 - PubMed
  12. JAMA. 2015 May 5;313(17):1728-35 - PubMed
  13. Hepatology. 2015 Jan;61(1):77-87 - PubMed
  14. N Engl J Med. 2013 Jan 3;368(1):45-53 - PubMed
  15. Lancet. 2014 Aug 2;384(9941):403-13 - PubMed
  16. Hepatology. 2014 Jan;59(1):318-27 - PubMed
  17. Am J Health Syst Pharm. 2015 Sep 1;72(17):1445-55 - PubMed
  18. Clin Pharmacokinet. 2016 May;55(5):605-13 - PubMed
  19. N Engl J Med. 1992 Dec 31;327(27):1899-905 - PubMed
  20. N Engl J Med. 2006 Dec 7;355(23 ):2444-51 - PubMed
  21. Gastroenterology. 2014 May;146(5):1176-92 - PubMed
  22. Lancet. 2014 Aug 2;384(9941):414-26 - PubMed
  23. Lancet. 1998 Oct 31;352(9138):1426-32 - PubMed
  24. Hepatology. 2002 Sep;36(3):729-36 - PubMed
  25. Ann Intern Med. 2015 Jul 7;163(1):1-13 - PubMed
  26. Curr Opin Pharmacol. 2014 Oct;18:9-17 - PubMed
  27. Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1 - PubMed
  28. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  29. Lancet Infect Dis. 2013 May;13(5):401-8 - PubMed
  30. Clin Infect Dis. 2012 Sep;55(5):728-36 - PubMed
  31. N Engl J Med. 2015 Dec 31;373(27):2599-607 - PubMed
  32. Ann Pharmacother. 2015 Mar;49(3):343-50 - PubMed
  33. N Engl J Med. 2004 Jul 29;351(5):438-50 - PubMed
  34. Virology. 2015 Feb;476:168-79 - PubMed
  35. Ann Pharmacother. 2014 May 8;48(8):1019-1029 - PubMed
  36. Hepatology. 2016 Aug;64(2):360-9 - PubMed
  37. Ann Pharmacother. 2016 Jan;50(1):39-46 - PubMed
  38. N Engl J Med. 2015 Aug 20;373(8):705-13 - PubMed
  39. Nat Med. 2013 Jul;19(7):837-49 - PubMed
  40. Nat Rev Microbiol. 2007 Jun;5(6):453-63 - PubMed
  41. J Hepatol. 2014 Nov;61(1 Suppl):S58-68 - PubMed
  42. Drugs. 2015 Feb;75(2):183-96 - PubMed
  43. Arch Intern Med. 2011 Feb 14;171(3):242-8 - PubMed
  44. Clin Ther. 2015 Feb 1;37(2):243-67 - PubMed
  45. N Engl J Med. 2004 May 27;350(22):2265-71 - PubMed
  46. N Engl J Med. 2014 May 15;370(20):1889-98 - PubMed
  47. Lancet. 2013 Jun 15;381(9883):2100-7 - PubMed
  48. Hepatology. 2016 Aug;64(2):370-80 - PubMed
  49. J Hepatol. 1999;31 Suppl 1:9-16 - PubMed
  50. Top Antivir Med. 2015 May-Jun;23(2):92-6 - PubMed
  51. N Engl J Med. 2013 Aug 15;369(7):679-80 - PubMed
  52. Am J Transplant. 2015 May;15(5):1313-22 - PubMed
  53. N Engl J Med. 2014 Dec 18;371(25):2375-82 - PubMed
  54. N Engl J Med. 2015 Dec 31;373(27):2618-28 - PubMed
  55. Clin Infect Dis. 2012 Jul;55 Suppl 1:S43-8 - PubMed
  56. Science. 1989 Apr 21;244(4902):359-62 - PubMed
  57. Antimicrob Agents Chemother. 2014 Dec;58(12):7416-23 - PubMed
  58. Expert Opin Pharmacother. 2014 Apr;15(5):711-6 - PubMed
  59. Lancet. 2015 Mar 21;385(9973):1124-35 - PubMed
  60. N Engl J Med. 2014 Apr 24;370(17):1594-603 - PubMed
  61. Hepatology. 2009 Aug;50(2):407-13 - PubMed
  62. Hepatology. 2015 Sep;62(3):932-54 - PubMed
  63. Lancet. 2008 Jul 26;372(9635):321-32 - PubMed
  64. Expert Opin Investig Drugs. 2015;24(8):1111-21 - PubMed
  65. Med Lett Drugs Ther. 2014 Jan 6;56(1433):1-3 - PubMed
  66. Nature. 2001 Apr 19;410(6831):974-9 - PubMed
  67. N Engl J Med. 2014 May 22;370(21):1973-82 - PubMed
  68. N Engl J Med. 2011 Jun 23;364(25):2429-38 - PubMed
  69. Hepatology. 2016 May;63(5):1493-505 - PubMed
  70. N Engl J Med. 2009 Aug 6;361(6):580-93 - PubMed
  71. Clin Microbiol Rev. 2010 Jan;23(1):160-201 - PubMed
  72. Minerva Gastroenterol Dietol. 2006 Jun;52(2):107-23 - PubMed
  73. N Engl J Med. 2011 Mar 31;364(13):1195-206 - PubMed
  74. Hepatology. 2014 Jan;59(1):46-8 - PubMed
  75. J Viral Hepat. 2015 Nov;22(11):861-70 - PubMed
  76. Adv Virus Res. 2008;71:51-133 - PubMed
  77. J Hepatol. 2012 Jun;56(6):1247-53 - PubMed
  78. N Engl J Med. 2015 Aug 20;373(8):714-25 - PubMed
  79. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  80. J Viral Hepat. 2015 Dec;22(12 ):1011-9 - PubMed
  81. N Engl J Med. 2014 May 15;370(20):1879-88 - PubMed
  82. JAMA. 2015 May 12;313(18):1857-8 - PubMed
  83. Med Lett Drugs Ther. 2015 Apr 13;57(1466):58 - PubMed
  84. Nature. 2009 Sep 17;461(7262):399-401 - PubMed
  85. Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63 - PubMed
  86. Drugs. 2015 Jun;75(9):1027-38 - PubMed
  87. BMJ. 2014 Jul 07;348:g3308 - PubMed
  88. JAMA Intern Med. 2015 Feb;175(2):178-85 - PubMed
  89. Gastroenterology. 2004 Mar;126(3):840-8 - PubMed
  90. Nature. 2010 May 6;465(7294):96-100 - PubMed
  91. Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2 - PubMed
  92. Gastroenterology. 2014 Aug;147(2):359-365.e1 - PubMed
  93. JAMA. 2015 May 5;313(17):1736-44 - PubMed
  94. N Engl J Med. 2013 May 16;368(20):1907-17 - PubMed
  95. Drugs. 2014 Sep;74(13):1559-71 - PubMed
  96. Chin Med J (Engl). 2014;127(7):1206-10 - PubMed
  97. Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50 - PubMed
  98. J Hepatol. 2013 Aug;59(2):375-82 - PubMed
  99. N Engl J Med. 2013 Jan 3;368(1):34-44 - PubMed
  100. Hepatology. 2015 Jan;61(1):41-5 - PubMed
  101. Hepatology. 2013 Apr;57(4):1333-42 - PubMed
  102. Ann Pharmacother. 2015 May;49(5):566-81 - PubMed
  103. N Engl J Med. 2004 Jul 29;351(5):451-9 - PubMed

Publication Types